Iodized Ethyl Esters Of Poppyseed Fatty Acids
Hepatocellular Carcinoma
Explore 499 assets in Hepatocellular Carcinoma →Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
RWTH Aachen University
Modality
mixture
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
74High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05842174CT.gov Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT07487662CT.gov TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk | — | Not Yet Recruiting | — | — | — |
NCT07340502CT.gov TACE Versus HAIC, Combined With PD-1 Inhibitors and Lenvatinib for Unresectable Hepatocellular Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT07309419CT.gov A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT07100405CT.gov TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma: Study on Efficacy and Immune Microenvironment | — | Recruiting | — | — | — |
NCT07186621CT.gov Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC | — | Recruiting | — | — | — |
NCT06995105CT.gov Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT06896396CT.gov Icaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT06844357CT.gov A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer. | — | Recruiting | — | — | — |
NCT07157969CT.gov ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC | — | Recruiting | — | — | — |
Show 90 more trialsShow fewer
NCT07009470CT.gov A Multicenter, Prospective Study of Perioperative Finotonlimab Combined With Bevacizumab in Resectable Hepatocellular Carcinoma Patients With High-Risk Factors for Recurrence | — | Active Not Recruiting | — | — | — |
NCT06740370CT.gov TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT06609850CT.gov The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT06371157CT.gov A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT05984511CT.gov TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT | — | Recruiting | — | — | — |
NCT05920863CT.gov Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors | — | Recruiting | — | — | — |
NCT07321613CT.gov Effect of TCC Cocktail Combined With TACE Versus TACE Alone on Survival in uHCC Patients | — | Completed | — | — | — |
NCT05576909CT.gov Donafenib Combined With Hepatic Artery Chemoembolization for Perioperative Treatment of Liver Transplantation | — | Unknown | — | — | — |
NCT06090656CT.gov Bevacizumab in Combination With Sintilimab Versus Transcatheter Arterial Chemoembolization for the Treatment of Intermediate Stage Hepatocellular Carcinoma (Beyond Up-To-Seven Criteria) | — | Recruiting | — | — | — |
NCT05578430CT.gov AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING) | — | Unknown | — | — | — |
NCT05332821CT.gov TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC | — | Completed | — | — | — |
NCT05332496CT.gov TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC | — | Completed | — | — | — |
NCT05811481CT.gov Regorafenib Alone or in Combined With Transcatheter Arterial ChEmoembolization in Treatment of Advanced Hepatocellular Carcinoma After First Line Targeted Therapy | — | Unknown | — | — | — |
NCT05435014CT.gov T-ACE Oil by TAE/TACE in Patients With Hepatocellular Carcinoma | — | Suspended | — | — | — |
NCT05320692CT.gov A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma | — | Active Not Recruiting | — | — | — |
NCT05319431CT.gov A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC | — | Active Not Recruiting | — | — | — |
NCT05213221CT.gov Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC Patients | — | Completed | — | — | — |
NCT05717738CT.gov Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT05171166CT.gov Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial. | — | Terminated | — | — | — |
NCT04981665CT.gov A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection | — | Unknown | — | — | — |
NCT04992143CT.gov TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC | — | Unknown | — | — | — |
NCT05056337CT.gov Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC | — | Unknown | — | — | — |
NCT04954794CT.gov TACE Combined with Sintilimab Plus Bevacizumab Biosimilar in Patients with Advanced Hepatocellular Carcinoma (TASK-02) | — | Completed | — | — | — |
NCT04803994CT.gov The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma | — | Recruiting | — | — | — |
NCT06848556CT.gov Evaluate the Effect of Tirazamine on Primary Liver Cancer. | — | Terminated | — | — | — |
NCT04842565CT.gov cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria | — | Completed | — | — | — |
NCT03937830CT.gov Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma | — | Active Not Recruiting | — | — | — |
NCT05535998CT.gov TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTT | — | Completed | — | — | — |
NCT04653389CT.gov Perioperative Therapy for Hepatocellular Carcinoma | — | Terminated | — | — | — |
NCT04988945CT.gov TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT04523467CT.gov Anti-angiogenic Targeted Drugs Plus Rg3 to Improve the Efficacy of TACE for Unresectable Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT04997850CT.gov The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT04178642CT.gov The Impact on Hepatic Recurrence After Adjuvant Chemotherapy With Intraarterial Infusion of Idarubicin-Lipiodol | — | Withdrawn | — | — | — |
NCT04340193CT.gov A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer | — | Completed | — | — | — |
NCT04559607CT.gov TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma | — | Unknown | — | — | — |
NCT04246177CT.gov Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012) | — | Completed | — | — | — |
NCT04297280CT.gov TACE Combined with Anti-PD-1 Antibody in Patients with Advanced Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT04213118CT.gov Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence | — | Unknown | — | — | — |
NCT04220944CT.gov Combined Locoregional Treatment With Immunotherapy for Unresectable HCC. | — | Active Not Recruiting | — | — | — |
NCT04103398CT.gov TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT04048317CT.gov Effectiveness of Drug Eluting TACE in Primary HCC | — | Unknown | — | — | — |
NCT04066543CT.gov TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients | — | Unknown | — | — | — |
NCT04417764CT.gov TACE Combined With PD-1 Knockout Engineered T Cell in Advanced Hepatocellular Carcinoma. | — | Unknown | — | — | — |
NCT03608878CT.gov Adagloxad Simolenin/OBI-821 in Combination With TACE Therapy in HCC Patients With GALNT14-rs9679162-non-TT Genotype | — | Terminated | — | — | — |
NCT03914352CT.gov A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic Resection | — | Unknown | — | — | — |
NCT03817736CT.gov Sequential TACE and SBRT Followed by ImmunoTherapy for Downstaging HCC for Hepatectomy | — | Completed | — | — | — |
NCT02436902CT.gov Adjuvant Therapies for Patients With HCC and MVI | — | Unknown | — | — | — |
NCT05307926CT.gov Postoperative Adjuvant Therapy of HCC Based on PD-1 | — | Completed | — | — | — |
NCT03791918CT.gov Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria | — | Withdrawn | — | — | — |
NCT03782831CT.gov TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCC | — | Withdrawn | — | — | — |
NCT03730675CT.gov Irradiation Stent Placement Plus TACE for HCC and PVTT | — | Unknown | — | — | — |
NCT02715492CT.gov Role of (LMWH) in Prevention of Thromboembolic Complication After (TACE) in Hepatocellular Carcinoma. | — | Unknown | — | — | — |
NCT03727633CT.gov Hepatocellular Carcinoma on Cirrhosis With Child A/B7 and Hepatic Intra Arterial Injection of Idarubicin/Lipiodol Emulsion | — | Terminated | — | — | — |
NCT03510416CT.gov Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT03511703CT.gov The Study of The Treatment of Postoperative Adjuvant Apatinib vs. TACE in Hepatocellular Carcinoma Patients | — | Unknown | — | — | — |
NCT03398122CT.gov Study of Apatinib Combined With TACE in Advance Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT03235167CT.gov Cytidine-phosphate-guanosine (CpG) DNA in Hepatocellular Carcinoma Combination Therapy | — | Unknown | — | — | — |
NCT02997956CT.gov Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE) | — | Withdrawn | — | — | — |
NCT03259867CT.gov Combination of TATE and PD-1 Inhibitor in Liver Cancer | — | Recruiting | — | — | — |
NCT03086564CT.gov A Basic-clinical Translational Research in Hepatitis B Virus (HBV)-Specific Antigen Peptides and HepG2 Cell Lysate Co-activated Dendritic Cells Combined With Transarterial Chemoembolization (TACE) in HBV-related HCC Treatment (BTRHBVAPHCLCDCCTCHBVHCCT) | — | Completed | — | — | — |
NCT03575806CT.gov Combine TACE and Autologous Tcm Immunotherapy Versus TACE Alone for HCC With MVI After Radical Resection | — | Completed | — | — | — |
NCT02956772CT.gov Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients | — | Unknown | — | — | — |
NCT02524119CT.gov LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma | — | Terminated | — | — | — |
NCT02702323CT.gov Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical Study | — | Unknown | — | — | — |
NCT02338297CT.gov Therapeutic Effect of Ethanol-gelfoam Mixture for the Treatment of Arterioportal Shunts (APS) in Patients With HCC | — | Unknown | — | — | — |
NCT02630108CT.gov TACE Combined With Synchronous Radiofrequency /Microwave Ablation to Treat Large and Huge Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT02638857CT.gov Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT02537158CT.gov Sorafenib and TACE as Adjuvant Therapy for MVI in HCC Patients After Radical Resection | — | Unknown | — | — | — |
NCT02529761CT.gov TACE With or Without Sorafenib in Intermediate Stage Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT02504983CT.gov Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE in Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT03007225CT.gov Efficacy and Safety of Drug Eluting Beads TACE in Treatment of HCC in Egyptian Patients | — | Completed | — | — | — |
NCT02794337CT.gov TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer | — | Unknown | — | — | — |
NCT01906216CT.gov Sorafenib Chemoembolization Evaluation Controlled Trial | — | Completed | — | — | — |
NCT01861912CT.gov Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT01853618CT.gov Tremelimumab With Chemoembolization or Ablation for Liver Cancer | — | Completed | — | — | — |
NCT02724358CT.gov Rg3 in Combination With TACE in Hepatocellular Carcinoma Patients With High Expression of Notch1 | — | Completed | — | — | — |
NCT01489410CT.gov Comparing Lipiodol/Ethanol With Drug-eluting Beads (DEB) for Hepatocellular Carcinoma | — | Withdrawn | — | — | — |
NCT01715532CT.gov Role of Huachansu in Treating Hepatocellular Carcinoma and the Correlation With Na+/K+-ATPase | — | Unknown | — | — | — |
NCT01605734CT.gov TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT01966133CT.gov TACE as an Adjuvant Therapy After Hepatectomy for HCC | — | Unknown | — | — | — |
NCT01126463CT.gov 188RE-SSS Lipiodol to Treat HepatoCellular Carcinomas | — | Completed | — | — | — |
NCT00960518CT.gov TACE and Adefovir Compared With Transarterial Chemoembolization (TACE) Alone for Hepatitis B Virus (HBV)-Related Unresectable Hepatocellular Carcinoma (HCC) | — | Unknown | — | — | — |
NCT00921531CT.gov Adjuvant Therapy With Thalidomide for Chemoembolization in Advanced Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT00820053CT.gov A Trial of Adjuvant Transarterial Chemoembolization (TACE) for Preventing Tumor Recurrence After Liver Resection | — | Completed | — | — | — |
NCT00829465CT.gov Clinical Research of Licartin Combined With TACE in the Treatment of Unresectable Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT00827554CT.gov The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT00817895CT.gov Intraoperative Chemotherapy Against Hepatocellular Carcinoma Recurrence | — | Completed | — | — | — |
NCT00576056CT.gov Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC | — | Terminated | — | — | — |
NCT00470340CT.gov Chemotherapy or Not, Following Complete Treatment of Hepatic Cancer in Cirrhotic Patients | — | Terminated | — | — | — |
NCT00116454CT.gov Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatocellular Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Iodized Ethyl Esters Of Poppyseed Fatty Acids (this asset) | RWTH Aachen University | Approved | BB · 70 |
| Adefovir | Bukwang Pharmaceutical | P4 | BBB |
| Huaier Granule | Tongji Hospital | P4 | BBB |
| Fluorouracilum | Li Qiang | P4 | BBB |
| Oxaliplatin | Li Qiang | P4 | BBB |
| Theprubicin | RWTH Aachen University | P4 | BB |
| Adriamycin | VA Office of Research and Development | P4 | BB |
| nrt6003 | Second Affiliated Hospital of Guangzhou Medical University | P3 | BB |
| Epirubicin | Fudan University | P4 | BB |
+42 more in the Hepatocellular Carcinoma cohort
Other indications for Iodized Ethyl Esters Of Poppyseed Fatty Acids
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Viral Hepatitis | — | P3 | BB · 64 |
| Liver Cancer | — | P4 | BB · 64 |
| Liver And Intrahepatic Bile Duct Neoplasm | — | P3 | B · 61 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Iodized Ethyl Esters Of Poppyseed Fatty Acids in Hepatocellular Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/iodized-ethyl-esters-of-poppyseed-fatty-acids-hepatocellular-carcinoma-111580
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →